Page 1 | Search Results | Blood | American Society of Hematology

1-17 of 17

Sort by

Sort Order Select

Journal Articles

Treatment Patterns and Outcomes in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma: Experience from a Single UK Centre

John Radford, Ellie White, Felipe A. Castro, PhD, Anshuman Chaturvedi, FRCPath, Nathalie Spielewoy, PhD, Adam Gibb, MBBS, Andy Surinach, MPH, Kim Linton, PhD, Aijing Shang, MD PhD, Michael Wenger, MD

Blood (2019) 134 (Supplement_1): 2917.

https://doi.org/10.1182/blood-2019-123664

Published: 2019

Journal Articles

PD-L1 Blockade with Atezolizumab in Higher-Risk Myelodysplastic Syndrome: An Initial Safety and Efficacy Analysis

Aaron T. Gerds, MDMS, Bart L Scott, MD, Peter L Greenberg, MD, Samer K. Khaled, MD, Tara L Lin, MD, Daniel A Pollyea, MD, Amit Verma, MD, Monique Dail, Cherie Green, Connie Ma, Bruno C Medeiros, Patrick Phuong, Michael Wenger, Mark Yan, William B. Donnellan, MD

Blood (2018) 132 (Supplement 1): 466.

https://doi.org/10.1182/blood-2018-99-118577

Published: 2018

Journal Articles

Atezolizumab in Combination with Daratumumab with or without Lenalidomide or Pomalidomide: A Phase Ib Study in Patients with Multiple Myeloma

Hearn Jay Cho, MD, Luciano J Costa, MD PhD, Faith E. Davies, MD, Natalia Neparidze, MD, Ravi Vij, Yuning Feng, Anastasia Teterina, Elisabeth Wassner Fritsch, Michael Wenger, Jonathan L Kaufman, MD

Blood (2018) 132 (Supplement 1): 597.

https://doi.org/10.1182/blood-2018-99-114960

Published: 2018

Journal Articles

Safety and Efficacy of Atezolizumab in Combination with Rituximab Plus CHOP in Previously Untreated Patients with Diffuse Large B-Cell Lymphoma (DLBCL): Primary Analysis of a Phase I/II Study

Anas Younes, MD, John M Burke, Bruce Cheson, MD, Catherine Diefenbach, MD, Silvia Ferrari, Uwe Hahn, Eliza Hawkes, Cyrus Khan, Izidore S. Lossos, MD, Gerardo Musuraka, Monica Tani, Umberto Vitolo, Sam Yuen, Mikkel Z Oestergaard, Surya Chitra, Michael Wenger, Tina Nielsen, Gila Sellam, Jeff Sharman, MD

Blood (2018) 132 (Supplement 1): 2969.

https://doi.org/10.1182/blood-2018-99-116678

Published: 2018

Journal Articles

Atezolizumab in Combination with Obinutuzumab and Lenalidomide Demonstrates Favorable Activity and Manageable Toxicity in Patients with Relapsed/Refractory Follicular Lymphoma (FL): An Interim Analysis of a Phase Ib/II Trial

Gilles Salles, MD PhD, Nilanjan Ghosh, MD PhD, Izidore S. Lossos, MD, Maria Lia Palomba, MD, Amitkumar Mehta, MD, Olivier Casasnovas, Don Stevens, MD, Ana Abajo, Tina Nielsen, Surya Chitra, Michael Wenger, Franck Morschhauser

Blood (2018) 132 (Supplement 1): 1603.

https://doi.org/10.1182/blood-2018-99-114992

Published: 2018

Journal Articles

MYC Pathway Activation Is Frequently Observed in Treatment-Naive CLL and Defines a Subgroup with Particular Benefit from the Addition of Rituximab to Chemotherapy

Johannes Bloehdorn, MD, Julia Krzykalla, MSc, Billy Michael Chelliah Jebaraj, PhD, Karlheinz Holzmann, Dr. rer. nat., Jasmin Bahlo, PhD, Sandra Robrecht, PhD, Kathryn Humphrey, Michael Wenger, Eugen Tausch, MD, Christof Schneider, MD, Lars Bullinger, MD, Kirsten Fischer, MD, Michael Hallek, MD, Daniel Mertens, Axel Benner, Hartmut Döhner, MD, Stephan Stilgenbauer

Blood (2018) 132 (Supplement 1): 1866.

https://doi.org/10.1182/blood-2018-99-116937

Published: 2018

Journal Articles

A Novel Prognostic Model That Is Superior to FLIPI-1 and FLIPI-2 and Integrates Clinical and Treatment Factors to Predict Progression-Free Survival and Early Treatment Failure in Patients with Follicular Lymphoma in the GALLIUM Trial

Farheen Mir, MBBS, Andrew Grigg, Michael Herold, Wolfgang Hiddemann, Robert Marcus, John F. Seymour, MBBS, PhD, Christopher R Bolen, Andrea Knapp, Aino Launonen, Federico Mattiello, Tina Nielsen, Mikkel Z Oestergaard, Michael Wenger, Carla Casulo, MD

Blood (2018) 132 (Supplement 1): 2872.

https://doi.org/10.1182/blood-2018-99-114620

Published: 2018

Journal Articles

Obinutuzumab (GA101) in relapsed/refractory chronic lymphocytic leukemia: final data from the phase 1/2 GAUGUIN study

Guillaume Cartron, Sophie de Guibert, Marie-Sarah Dilhuydy, Franck Morschhauser, Veronique Leblond, Jehan Dupuis, Beatrice Mahe, Reda Bouabdallah, Guiyuan Lei, Michael Wenger, Elisabeth Wassner-Fritsch, Michael Hallek

Blood (2014) 124 (14): 2196–2202.

https://doi.org/10.1182/blood-2014-07-586610

Published: 2014

Includes: Supplemental data

Journal Articles

Obinutuzumab (GA101) plus CHOP or FC in relapsed/refractory follicular lymphoma: results of the GAUDI study (BO21000)

John Radford, Andrew Davies, Guillaume Cartron, Franck Morschhauser, Gilles Salles, Robert Marcus, Michael Wenger, Guiyuan Lei, Elisabeth Wassner-Fritsch, Umberto Vitolo

Blood (2013) 122 (7): 1137–1143.

https://doi.org/10.1182/blood-2013-01-481341

Published: 2013

Journal Articles

The role of sex and weight on rituximab clearance and serum elimination half-life in elderly patients with DLBCL

Carsten Müller, Niels Murawski, Martin H. J. Wiesen, Gerhard Held, Viola Poeschel, Samira Zeynalova, Michael Wenger, Christina Nickenig, Norma Peter, Eva Lengfelder, Bernd Metzner, Tanja Rixecker, Carsten Zwick, Michael Pfreundschuh, Marcel Reiser

Blood (2012) 119 (14): 3276–3284.

https://doi.org/10.1182/blood-2011-09-380949

Published: 2012

Journal Articles

Serum Factors Predict Therapeutic Outcome In Patients with Chronic Lymphocytic Leukemia Treated In the CLL8 Trial of the German CLL Study Group (GCLLSG)

Anna Fink, MD, Natali Pflug, MD, Raymonde Busch, Gunter R. Fingerle-Rowson, MD, PhD, Barbara Eichhorst, MD, Clemens-Martin Wendtner, MD, Dirk Winkler, MD, Andreas Buehler, MD, Myriam Mendila, MD, Michael Wenger, MD, Hartmut Dohner, MD, Stephan Stilgenbauer, M.D., Michael Hallek, MD, Kirsten Fischer, MD

Blood (2010) 116 (21): 918.

https://doi.org/10.1182/blood.V116.21.918.918

Published: 2010

Journal Articles

Chemoimmunotherapy with Chlorambucil and the Type II CD20-Antibody GA101 In Patients with Chronic Lymphocytic Leukemia and Comorbidity: Results of the Run-In Phase of the CLL11 (BO21004) Trial

Valentin Goede, Kirsten Fischer, Busch Raymonde, Jaeger Ulrich, Marie-Sarah Dilhuydy, Nicholas Wickham, Sophie De Guibert, Anna Maria Fink, Susanne Hagist, Natali Pflug, Jasmin Bahlo, Gabriele Kranz, Gabriel Bieska, Kathryn Humphrey, Helen Bishop, Michael Wenger, Michael Hallek

Blood (2010) 116 (21): 1387.

https://doi.org/10.1182/blood.V116.21.1387.1387

Published: 2010

Journal Articles

Genetics of Patients with F-Refractory CLL or Early Relapse After FC or FCR: Results From the CLL8 Trial of the GCLLSG

Thorsten Zenz, MD, Raymonde Busch, Anna Fink, MD, Dirk Winkler, MD, Kirsten Fischer, MD, Andreas Bühler, MD, Patrick Hoth, Gunter R. Fingerle-Rowson, MD, PhD, Michael Kneba, MD, PhD, Sebastian Boettcher, MD, Ulrich Jäger, MD, Myriam Mendila, MD, Michael Wenger, MD, Peter Lichter, PhD, Michael Hallek, MD, Hartmut Döhner, MD, Stephan Stilgenbauer, MD

Blood (2010) 116 (21): 2427.

https://doi.org/10.1182/blood.V116.21.2427.2427

Published: 2010

Journal Articles

Promising Efficacy with the New Anti-CD20 Antibody GA101 In Heavily Pre-Treated NHL Patients – Updated Results with Encouraging Progression Free Survival (PFS) Data From a Phase II Study In Patients with Relapsed/Refractory Indolent NHL (iNHL)

Gilles Andre Salles, MD, PhD, Franck Morschhauser, MD, PhD, Catherine Thieblemont, MD, PhD, Philippe Solal-Céligny, MD, Thierry Lamy, MD, PhD, Herve Tilly, MD, Pierre Feugier, MD, PhD, Steven Le Gouill, MD, Emmanuel Gyan, MD, PhD, Reda Bouabdallah, MD, Michael Wenger, MD, Joe Birkett, PhD, Guillaume Cartron, MD, PhD

Blood (2010) 116 (21): 2868.

https://doi.org/10.1182/blood.V116.21.2868.2868

Published: 2010

Journal Articles

Genomic Aberrations, VH Mutation Status and Outcome after Fludarabine and Cyclophosphamide (FC) or FC Plus Rituximab (FCR) in the CLL8 Trial

Stephan Stilgenbauer, Thorsten Zenz, Dirk Winkler, Andreas Bühler, Raymonde Busch, Günther Fingerle-Rowson, Kirsten Fischer, Anna- Maria Fink, Ulrich Jäger, Sebastian Böttcher, Michael Kneba, Michael Wenger, Myriam Mendila, Michael Hallek, Hartmut Döhner

Blood (2008) 112 (11): 781.

https://doi.org/10.1182/blood.V112.11.781.781

Published: 2008

Journal Articles

Safety in Patients Receiving Maintenance Rituximab for Follicular Lymphoma: Results from Phase IIIb MAXIMA Trial.

Mathias Witzens-Harig, Joachim Hipp, Anthony D. Ho, Nikolai Nikolov, Daniel Thurley, Manfred Hensel, MD, Stefan Oertel, Michael Wenger

Blood (2008) 112 (11): 1998.

https://doi.org/10.1182/blood.V112.11.1998.1998

Published: 2008

Journal Articles

Dose-Dense Rituximab in Combination with Biweekly CHOP-14 for Elderly Patients with Diffuse Large B-Cell Lymphoma (DLBCL): Results of a Phase-I/II and Pharmacokinetic Study of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL).

Viola Poeschel, MD, Maike Nickelsen, M.D., Mathias Hanel, M.D., Stephan Kremers, M.D., Swen Wessendorf, M.D., Hartmut Eimermacher, M.D., Norma Peter, M.D., Michael Wenger, M.D., Marcel Reiser, M.D., Norbert Schmitz, M.D., Michael Pfreundschuh, M.D.

Blood (2006) 108 (11): 2738.

https://doi.org/10.1182/blood.V108.11.2738.2738

Published: 2006

NARROW

Treatment Patterns and Outcomes in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma: Experience from a Single UK Centre

PD-L1 Blockade with Atezolizumab in Higher-Risk Myelodysplastic Syndrome: An Initial Safety and Efficacy Analysis

Atezolizumab in Combination with Daratumumab with or without Lenalidomide or Pomalidomide: A Phase Ib Study in Patients with Multiple Myeloma

Safety and Efficacy of Atezolizumab in Combination with Rituximab Plus CHOP in Previously Untreated Patients with Diffuse Large B-Cell Lymphoma (DLBCL): Primary Analysis of a Phase I/II Study

Atezolizumab in Combination with Obinutuzumab and Lenalidomide Demonstrates Favorable Activity and Manageable Toxicity in Patients with Relapsed/Refractory Follicular Lymphoma (FL): An Interim Analysis of a Phase Ib/II Trial

MYC Pathway Activation Is Frequently Observed in Treatment-Naive CLL and Defines a Subgroup with Particular Benefit from the Addition of Rituximab to Chemotherapy

A Novel Prognostic Model That Is Superior to FLIPI-1 and FLIPI-2 and Integrates Clinical and Treatment Factors to Predict Progression-Free Survival and Early Treatment Failure in Patients with Follicular Lymphoma in the GALLIUM Trial

Obinutuzumab (GA101) in relapsed/refractory chronic lymphocytic leukemia: final data from the phase 1/2 GAUGUIN study

Obinutuzumab (GA101) plus CHOP or FC in relapsed/refractory follicular lymphoma: results of the GAUDI study (BO21000)

The role of sex and weight on rituximab clearance and serum elimination half-life in elderly patients with DLBCL

Serum Factors Predict Therapeutic Outcome In Patients with Chronic Lymphocytic Leukemia Treated In the CLL8 Trial of the German CLL Study Group (GCLLSG)

Chemoimmunotherapy with Chlorambucil and the Type II CD20-Antibody GA101 In Patients with Chronic Lymphocytic Leukemia and Comorbidity: Results of the Run-In Phase of the CLL11 (BO21004) Trial

Genetics of Patients with F-Refractory CLL or Early Relapse After FC or FCR: Results From the CLL8 Trial of the GCLLSG

Promising Efficacy with the New Anti-CD20 Antibody GA101 In Heavily Pre-Treated NHL Patients – Updated Results with Encouraging Progression Free Survival (PFS) Data From a Phase II Study In Patients with Relapsed/Refractory Indolent NHL (iNHL)

Genomic Aberrations, VH Mutation Status and Outcome after Fludarabine and Cyclophosphamide (FC) or FC Plus Rituximab (FCR) in the CLL8 Trial

Safety in Patients Receiving Maintenance Rituximab for Follicular Lymphoma: Results from Phase IIIb MAXIMA Trial.

Dose-Dense Rituximab in Combination with Biweekly CHOP-14 for Elderly Patients with Diffuse Large B-Cell Lymphoma (DLBCL): Results of a Phase-I/II and Pharmacokinetic Study of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL).

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only